Skip to content
Covid-19 variant taken from Sanofi, GSK shows strong response to Omicron in studies

A Covid-19 vaccine developed by Sanofi SA and GSK PLC to target the beta strain of the virus produced a stronger antibody response against Omicron variants when given as a booster compared to some first-generation vaccines, according to two studies.

The findings are the latest indication that modifying vaccines may nudge antibody responses toward new variants, possibly helping to boost immunity as the virus mutates. The study results could also be an opportunity for Sanofi and GSK, two vaccine giants that have been slow to develop vaccines against Covid-19, to play a role in providing boosters.


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.